RedHill Biopharma Reports Operational Highlights and Third Quarter 2021 Financial Results Nov 30, 2021 07:00AM
RedHill Biopharma Announces Last Patient Randomized in Part A of Ongoing Phase 2/3 COVID-19 Study of Once-Daily Oral RHB-107 in Non-Hospitalized Patients Nov 15, 2021 07:00AM
RedHill Biopharma Presents New Talicia® and Movantik® Data Analyses at ACG 2021 Oct 25, 2021 07:01AM
Redhill Biopharma (REDIF) Announces New U.S. Patent Covering Talicia for H. pylori Infection Through 2034 Oct 12, 2021 07:02AM
RedHill Biopharma Announces New U.S. Patent Covering Talicia for H. pylori Infection Through 2034 Oct 12, 2021 07:00AM


Sep 23, 2021 07:00AM RedHill Biopharma Announces Settlement of Movantik® Patent Litigation with Aurobindo
Sep 13, 2021 07:00AM RedHill Biopharma Accelerates Ongoing U.S. Phase 2/3 COVID-19 Study of Once-Daily Oral RHB-107 in Non-Hospitalized Patients with South African Approval
Aug 19, 2021 07:00AM RedHill Biopharma to Host Second Quarter 2021 Financial Results and Operational Highlights Webcast on August 26, 2021
Jun 28, 2021 07:05AM Redhill Biopharma's (REDIF) Opaganib Inhibits COVID-19 Variants in Preclinical Study
Jun 28, 2021 07:00AM RedHill Biopharma's Opaganib Inhibits COVID-19 Variants in Preclinical Study
Mar 11, 2021 07:00AM RedHill Biopharma to Host Fourth Quarter and Full Year 2020 Financial Results and Operational Highlights Webcast on March 18, 2021
Mar 2, 2021 09:06AM ObvioHealth and RedHill Biopharma Launch First in Kind Remote COVID-19 Therapy Trial Incorporating Highest Level of At-home Patient Monitoring to Date
Feb 18, 2021 07:00AM RedHill Biopharma Strengthens Partnership with Cosmo Pharmaceuticals with Manufacturing Agreements for Movantik and RHB-204
Feb 17, 2021 07:00AM RedHill Biopharma Announces First Patient Dosed in U.S. Phase 2/3 COVID-19 Outpatient Study with RHB-107
Feb 9, 2021 07:00AM RedHill Biopharma to Present at SVB Leerink Global Healthcare and BIO CEO & Investor Conferences
Jan 29, 2021 07:05AM Redhill Biopharma (REDIF) Announces Positive DSMB Futility Review for Phase 2/3 COVID-19 Study of Opaganib
Jan 29, 2021 07:00AM RedHill Biopharma Announces Positive DSMB Futility Review for Phase 2/3 COVID-19 Study of Opaganib
Jan 28, 2021 07:27AM RedHill Biopharma Further Expands Opaganib Manufacturing Capacity for COVID-19 with Cosmo Pharmaceuticals
Jan 6, 2021 07:00AM RedHill Biopharma's RHB-204 Granted FDA Fast Track Designation for NTM Disease
Dec 11, 2020 08:05PM Annual Changes to the Nasdaq Biotechnology Index
Sep 23, 2020 07:03AM Veeva and Bioforum Partner with RedHill Biopharma to Maximize Value of Opaganib Phase 2/3 COVID-19 Clinical Data